- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02503982
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study
Valganciclovir is extensively used for cytomegalovirus (CMV) infection treatment and prophylaxis after solid organ transplantation (SOT). VGC dosing is problematic in children. valganciclovir has variable absorption and is renally excreted. Area Under the Curve (AUC) (0-24) of 40-60 mcg∙h/L is a predictive pharmacokinetic parameter of efficacy and safety. Dosing based on manufacturer recommendations is supra-therapeutic in most cases. A few published dosing algorithms result in AUC out of range.
Objective: To prospectively validate a Valganciclovir administration dosing regimen and compare it to other dosing algorithms.
Methods: Children after SOT at Schneider Children's Medical Center, the largest tertiary pediatric center in Israel, were prospectively studied, starting Dec 2014. The dosing regimen was derived from Seattle Children's Hospital guidelines; 14-16 mg/kg/dose. For impaired renal function, stratified dose reduction was used. Blood was withdrawn at steady state: 2, 5 and 10 hours post dosing. Drug level was analyzed by high pressure liquid chromatography (HPLC).
Study Overview
Status
Intervention / Treatment
Detailed Description
Valganciclovir is a novel drug used extensively as a prophylactic, preemptive and treatment agent for cytomegalovirus (CMV) infection after solid organ transplantation (SOT).
It is the valine ester prodrug of Ganciclovir,has a bioavailability of approximately 60%, which is up to 10-fold higher than oral ganciclovir .
Based on the correlation between the Pharmacokinetic (PK) of VGC and its clinical efficacy found in adult studies, AUC (0-24) of approximately 40-60 mcg∙h/mL has been described as predictive PK parameter of efficacy. Considering the mechanism of action of Valganciclovir , relationships of exposure-efficacy and exposure-safety are expected to be similar in children and adults.
In 2009, a new dosing algorithm incorporating both body surface area (BSA) and renal function was introduced by the manufacturer for infants and young children:
Dose (mg) =7 × BSA × CrCl
Very few studies have evaluated this dosing for infants and young children. In 2010 the FDA published a safety alert confirming the excessively high dosage calculated by the dosing algorithm in children with low body weight, low body surface area, and normal serum creatinine. This type of patient was not routinely observed in the clinical trials used to derive and confirm the pediatric dose.
As the body weight decreases and/or as the Creatinine Clearance (CrCl) increases excessively high doses are calculated. There is unproportional variability of doses calculated by the algorithm for infants and young children with normal renal function.
Doses can reach as high as 4 fold higher than the weight-based common dosing.
Objective:
- To prospectively validate a dosing regimen of Valganciclovir administration
- and to compare it to other dosing algorithms.
Methods:
This is a prospective study of all pediatric SOT recipients who were treated with oral valganciclovir. The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function as shown in the table. Max dose was 900 mg.
Measurement of valganciclovir levels After three days of consistent oral dosing to ensure steady-state concentrations, drug levels were measured at 2, 5 and 10 h following administration of the dose, and were analyzed at the pharmacologic laboratory of "Asaf HaRofeh Medical Center" using standard HPLC, with a lower limit of detection of 0.5 mcg/mL and a coefficient of variation of <10%. AUCs were calculated using the trapezoidal method.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Petah Tikva, Israel
- Schneider childrens medical center of Isreal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- children and adolescents 0-18 years old
- Solid Organ Transplantation admitted after transplantation
- Treatment with prophylactic Valganciclovir
- Glomerular Filtration Rate (GFR) >= 60 mL/min/1.73 m2
Exclusion Criteria:
- Treatment with ganciclovir IV
- Glomerular Filtration Rate (GFR) < 60 mL/min/1.73 m2
- Imipenem treatment
- Cluster organ transplanted -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Solid Organ Transplanted children
Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function.
Max dose was 900 mg.
|
The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function.
Max dose was 900 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC)
Time Frame: drug levels measured at 2, 5 and 10 h following administration of the dose on day 4 creating a 24 hours curve
|
Valganciclovir area under the curve (AUC) calculated with the trapezoidal method using drug levels measured at 2, 5 and 10 h, and extrapolated beyond the 10 hour time point to arrive at a 24-hour curve.
|
drug levels measured at 2, 5 and 10 h following administration of the dose on day 4 creating a 24 hours curve
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Liat Ashkenazy-Hofnung, MD, Schneider's Children Medical center of Isreal
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001-14-RMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection in Solid Organ Transplant Recipients
-
Michael IsonViraCor LaboratoriesCompletedInfection in Solid Organ Transplant Recipients | Awaiting Organ TransplantUnited States
-
Nuria LloberasMinisterio de Sanidad, Servicios Sociales e IgualdadCompletedInfection in Solid Organ Transplant RecipientsSpain
-
University of California, Los AngelesActive, not recruitingInfection in Solid Organ Transplant RecipientsUnited States
-
Duke UniversityBaylor College of Medicine; Children's Hospital of Philadelphia; Albert Einstein... and other collaboratorsCompletedRespiratory Viral Infection | Infection in Solid Organ Transplant Recipients | Complications of Organ TransplantUnited States
-
Methodist Health SystemCompletedInfection in Solid Organ Transplant RecipientsUnited States
-
Oxford ImmunotecCompletedInfection in Solid Organ Transplant RecipientsUnited States, United Kingdom, Canada
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedSolid Organ Transplant Recipients | Parent(s)/Guardian of Referenced Transplant RecipientsUnited States
-
Helio Tedesco Silva JuniorCompletedInfection in Solid Organ Transplant RecipientsBrazil
-
Paris Translational Research Center for Organ TransplantationCompletedOrgan Transplant Recipients
-
Bristol-Myers SquibbTerminatedImmunosuppression in Solid Organ TransplantFrance, Germany, Italy, United States, Austria, Canada, Spain, Argentina, Brazil
Clinical Trials on prophylactic Valganciclovir
-
Luis Eduardo Morales BuenrostroCompletedKidney Transplantation | Pharmacokinetics | Cytomegalovirus Infections | Therapeutic EquivalencyMexico
-
Stanford UniversityCompleted
-
Henares University HospitalUnknown
-
Jinling Hospital, ChinaActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Weill Medical College of Cornell University; University of North Carolina, Chapel Hill and other collaboratorsCompletedSarcomaUnited States
-
St. Olavs HospitalKarolinska University Hospital; University Hospital of North Norway; Norwegian...WithdrawnCranial Nerve Diseases | Facial Neuralgia | Trigeminal Neuralgia | Hemifacial Spasm
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI); Transfusion Medicine/Hemostasis...CompletedThrombocytopeniaUnited States
-
University of California, San FranciscoRoche Pharma AGCompletedHIV Infections | Cytomegalovirus InfectionsUnited States
-
Hoffmann-La RocheCompletedCytomegalovirus InfectionsUnited States
-
Dr. Reddy's Laboratories LimitedCompleted